On November 26, 2019  Absolem Health announced that it has entered into an L.O.I with Arev Brands (AREV.C) to “develop and produce mushroom extracts”, and potentially to collaborate to sell “mushroom-based products.”

With a stated mission of patients over profits, the Multidisciplinary Association for Psychedelic Studies (MAPS) is an outlier within the growing psychedelic treatment industry.

Yield Growth (BOSS.C) signed a distribution deal with Eurolife Brands to expand their subsidiary, Flourish Mushroom Labs, mushroom-infused coffee concoctions throughout Europe.

Psilocybin, a compound which has shown promise in counteracting treatment-resistant depression, leads the charge in helping JUUL users and smokers alike quit for good, according to a paper from Johns Hopkins University.

MindMed, owners of the iboga-related 18-MC drug, is going public after firming up its reverse take-over of Broadway Gold Mining (BRD.V).

Yield Growth (BOSS.C) has decided not to proceed with the previously announced investment into Absolem Health, instead advancing with their own subsidiary, Flourish Mushroom Labs, which has completed its acquisition of edible mushroom formulas.